top of page

In the context of the PRAISE e-cohort, we listed here scientific articles about OASI. This list is regularly updated.
Last update: January 29th, 2020
Search
May 4, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros et al., 2016. Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associ...
Feb 16, 2016
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Helen Gogas et al., 2016. BACKGROUND Immunotherapy for advanced melanoma induces serologic and clinical manifestations of autoimmunity....
Feb 13, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 [...]
TK. Eigentler et al., 2016. PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events. This...
Feb 10, 2016
Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab
Mary L. Disis, 2016 The use of immune checkpoint inhibitors, a new class of anticancer agents with a mechanism of action based on...
Feb 1, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM. Michot et al,. 2016. Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents...
Feb 1, 2016
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
DB Johnson et al., 2016 Importance Ipilimumab and other immune therapies are effective treatment options for patients with advanced...
Jan 14, 2016
Association of vitiligo with tumor response in patients with metastatic melanoma treated [...]
Camille Hua et al., 2016 IMPORTANCE Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo...
Dec 28, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al., 2015. Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained...
Oct 7, 2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of IRAEs [...]
M. Freeman-Keller et al., 2016. To date, immunotherapy for cancer has generated significant response rates and prolonged survival,...
Jul 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al., 2015. BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic...
Feb 3, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes [...]
DB. Johnson et al., 2015. Ipilimumab, a novel immune checkpoint inhibitor, is associated with long-term survival in approximately 20% of...
Mar 7, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma [...]
M. Ryder et al., 2014. Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4...
bottom of page